<SEC-DOCUMENT>0001213900-25-001408.txt : 20250107
<SEC-HEADER>0001213900-25-001408.hdr.sgml : 20250107
<ACCEPTANCE-DATETIME>20250107091117
ACCESSION NUMBER:		0001213900-25-001408
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250107
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250107
DATE AS OF CHANGE:		20250107

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Citius Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001506251
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				273425913
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38174
		FILM NUMBER:		25513585

	BUSINESS ADDRESS:	
		STREET 1:		11 COMMERCE DRIVE
		STREET 2:		1ST FLOOR
		CITY:			CRANFORD
		STATE:			NJ
		ZIP:			07016
		BUSINESS PHONE:		(908) 967-6676

	MAIL ADDRESS:	
		STREET 1:		11 COMMERCE DRIVE
		STREET 2:		1ST FLOOR
		CITY:			CRANFORD
		STATE:			NJ
		ZIP:			07016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Trail One, Inc.
		DATE OF NAME CHANGE:	20110314

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TrailOne, Inc.
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea0226990-8k_citius.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:CTXR="http://citiuspharma.com/20250107">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02D_US%2DGAAP%2D2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_039_CTXR_citiuspharma.com_20250107 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20250107_20250107 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DEntityCentralIndexKey_0001506251 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-01-07" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-01-07" id="Fact000004" name="dei:EntityCentralIndexKey">0001506251</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="ctxr-20250107.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-01-07">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001506251</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-01-07</xbrli:startDate>
        <xbrli:endDate>2025-01-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNITED
STATES</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SECURITIES
AND EXCHANGE COMMISSION</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Washington,
D.C. 20549</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM
<span id="xdx_90F_edei--DocumentType_c20250107__20250107_zl7Syt9Juc4d"><ix:nonNumeric contextRef="AsOf2025-01-07" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CURRENT
REPORT</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 13 or 15(d) of</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
Securities Exchange Act of 1934</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of Report (Date of earliest event reported) <span style="text-decoration: underline"><span id="xdx_909_edei--DocumentPeriodEndDate_c20250107__20250107_zdgtcTsAqw81"><ix:nonNumeric contextRef="AsOf2025-01-07" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">January 7, 2025</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_90A_edei--EntityRegistrantName_c20250107__20250107_z0BNeKZO5m5j"><ix:nonNumeric contextRef="AsOf2025-01-07" id="Fact000011" name="dei:EntityRegistrantName">Citius
Pharmaceuticals, Inc.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_904_edei--EntityIncorporationStateCountryCode_c20250107__20250107_zz7EZEaH8ouk"><ix:nonNumeric contextRef="AsOf2025-01-07" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
or other jurisdiction of incorporation)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--EntityFileNumber_c20250107__20250107_z9XjBHZ8uaO6"><ix:nonNumeric contextRef="AsOf2025-01-07" id="Fact000013" name="dei:EntityFileNumber">001-38174</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--EntityTaxIdentificationNumber_c20250107__20250107_zDHbedbHzScc"><ix:nonNumeric contextRef="AsOf2025-01-07" id="Fact000014" name="dei:EntityTaxIdentificationNumber">27-3425913</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File Number)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer <br/>
    Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.9pt; padding-left: 5.9pt; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--EntityAddressAddressLine1_c20250107__20250107_zw35ZgXB3Tkh"><ix:nonNumeric contextRef="AsOf2025-01-07" id="Fact000015" name="dei:EntityAddressAddressLine1">11
    Commerce Drive</ix:nonNumeric></span>, <span id="xdx_90C_edei--EntityAddressAddressLine2_c20250107__20250107_znQd94I67Ktf"><ix:nonNumeric contextRef="AsOf2025-01-07" id="Fact000016" name="dei:EntityAddressAddressLine2">1st Floor</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressCityOrTown_c20250107__20250107_zlUWwIKeGiCh"><ix:nonNumeric contextRef="AsOf2025-01-07" id="Fact000017" name="dei:EntityAddressCityOrTown">Cranford</ix:nonNumeric></span>, <span id="xdx_90B_edei--EntityAddressStateOrProvince_c20250107__20250107_zlB7GcfDHl1b"><ix:nonNumeric contextRef="AsOf2025-01-07" id="Fact000018" name="dei:EntityAddressStateOrProvince">NJ</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.9pt; padding-left: 5.9pt; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--EntityAddressPostalZipCode_c20250107__20250107_zpFRbhsd5L54"><ix:nonNumeric contextRef="AsOf2025-01-07" id="Fact000019" name="dei:EntityAddressPostalZipCode">07016</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.9pt; padding-left: 5.9pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of principal executive offices)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-right: 5.9pt; padding-left: 5.9pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip
    Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&#8217;s
telephone number, including area code <span style="text-decoration: underline">(<span id="xdx_90A_edei--CityAreaCode_c20250107__20250107_zulCDl0VMBAe"><ix:nonNumeric contextRef="AsOf2025-01-07" id="Fact000020" name="dei:CityAreaCode">908</ix:nonNumeric></span>) <span id="xdx_907_edei--LocalPhoneNumber_c20250107__20250107_zgrqIg5vCy3a"><ix:nonNumeric contextRef="AsOf2025-01-07" id="Fact000021" name="dei:LocalPhoneNumber">967-6677</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--WrittenCommunications_c20250107__20250107_zuwT9ecIahci"><ix:nonNumeric contextRef="AsOf2025-01-07" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications
    pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--SolicitingMaterial_c20250107__20250107_zBNbRKRpMIRl"><ix:nonNumeric contextRef="AsOf2025-01-07" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant
    to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--PreCommencementTenderOffer_c20250107__20250107_zxn0eWGmM3L8"><ix:nonNumeric contextRef="AsOf2025-01-07" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications
    pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--PreCommencementIssuerTenderOffer_c20250107__20250107_zJzuVdOmAotb"><ix:nonNumeric contextRef="AsOf2025-01-07" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications
    pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 5.9pt; padding-left: 5.9pt; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 5.9pt; padding-left: 5.9pt; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol(s)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-right: 5.9pt; padding-left: 5.9pt; text-align: center; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--Security12bTitle_c20250107__20250107_ziUX9pE2JXk5"><ix:nonNumeric contextRef="AsOf2025-01-07" id="Fact000026" name="dei:Security12bTitle">Common stock, $0.001 par
    value</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--TradingSymbol_c20250107__20250107_zheZa7B5VNf5"><ix:nonNumeric contextRef="AsOf2025-01-07" id="Fact000027" name="dei:TradingSymbol">CTXR</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <span id="xdx_901_edei--SecurityExchangeName_c20250107__20250107_zKGzykXbaSlc"><ix:nonNumeric contextRef="AsOf2025-01-07" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company <span id="xdx_907_edei--EntityEmergingGrowthCompany_c20250107__20250107_z6oSDIGUG9sj"><ix:nonNumeric contextRef="AsOf2025-01-07" format="ixt:booleanfalse" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
8.01 Other Events.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 58.5pt; text-indent: -58.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 7, 2025, Citius Pharmaceuticals, Inc. issued a press release announcing significant progress in preparations for the commercial
launch of LYMPHIR&#8482;, an innovative immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma
(CTCL).&#160;A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9.01. Financial Statements and Exhibits.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Exhibits</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="ea022699001ex99-1_citius.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release, dated January 7, 2025.</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Date File (embedded within the
    Inline XBRL document).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 180pt; text-indent: -108pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></span></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CITIUS PHARMACEUTICALS, INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: January 7, 2025</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Leonard
    Mazur</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leonard Mazur</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman and Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</span></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5lprWP+yjRUWsIkXE19CuEmyzZROrHslbGlvEZWFZZr4ZIQZiTStdIcN5kWdwxLqplEPI8YKMpkDvSDfbBPzN8aqtY2Vc9/7AlDyDnpmE8bjwQmdttcUyARkN5XQYT0DOktEcDjsRfPWUzEWXaJxWFShTwoGpYY1O8atPOKonGapfXdUJ2WoyCUSh7OU3xDKKYU+tehDfLGRZKoJBN4FYM90b71o+HZovCcsKa19ne/q/wQcM9EqX -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea022699001ex99-1_citius.htm
<DESCRIPTION>PRESS RELEASE, DATED JANUARY 7, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"><B>Exhibit
99.1</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Citius Pharmaceuticals and Citius Oncology Highlight
LYMPHIR Commercial Launch Planned for the First Half of 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>CRANFORD, N.J., January 7, 2025</B> &ndash;
Citius Pharmaceuticals, Inc. (&quot;Citius Pharma&quot; or the &quot;Company&quot;) (Nasdaq: CTXR) and its oncology-focused subsidiary,
Citius Oncology (Nasdaq: CTOR), today announced significant progress in preparations for the commercial launch of LYMPHIR&trade;, an innovative
immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Management is focused on making
LYMPHIR available to patients as quickly as possible, with preparations underway for launch in the first half of 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&ldquo;Since LYMPHIR&rsquo;s approval in August
2024, we have worked diligently toward supporting its successful launch. We are making significant progress to finalize our manufacturing,
marketing, reimbursement and sales efforts. This is a pivotal inflection point as we transition from clinical development to revenue generation.
Our strategy not only focuses on a successful U.S. market penetration, but also includes exploring additional growth opportunities, including
licensing partnerships in key international markets, for which discussions are underway, expanded indications for LYMPHIR, in addition
to LYMPHIR&rsquo;s potential as a combination immunotherapy. Our unwavering goal remains to deliver substantial value to patients, healthcare
providers, and shareholders by bringing this innovative cancer treatment to market,&rdquo; stated Leonard Mazur, Chairman and CEO of Citius
Pharmaceuticals and Citius Oncology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>Key Launch Preparations and Activities:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Manufacturing Scale-Up and Supply Chain Optimization:</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-size: 10pt">o</FONT></TD><TD STYLE="text-align: left">Secured commercial supply agreements with leading contract manufacturing organizations (CMOs).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-size: 10pt">o</FONT></TD><TD STYLE="text-align: left">First Year Launch Supply has been produced.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Healthcare Provider Engagement:</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-size: 10pt">o</FONT></TD><TD STYLE="text-align: left">Rolled out targeted education programs aimed at oncologists, hematologists, and other key medical professionals.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-size: 10pt">o</FONT></TD><TD STYLE="text-align: left">Launched an information platform that offers clinical data, dosing guidelines, and safety information
for healthcare providers.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Market Access and Reimbursement Efforts:</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-size: 10pt">o</FONT></TD><TD STYLE="text-align: left">Working closely with payers and healthcare providers to secure reimbursement pathways that facilitate
patient access.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-size: 10pt">o</FONT></TD><TD STYLE="text-align: left">Submitted an application for a unique J-code under the Healthcare Common Procedure Coding System (HCPCS)
to streamline reimbursement processes.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-size: 10pt">o</FONT></TD><TD STYLE="text-align: left">Secured LYMPHIR&rsquo;s inclusion in the National Comprehensive Cancer Network (NCCN) guidelines, a key
factor in influencing clinical decision-making and payer coverage in the U.S.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Patient Support Initiatives:</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-size: 10pt">o</FONT></TD><TD STYLE="text-align: left">Designed a patient assistance program to help with financial support and access to LYMPHIR.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-size: 10pt">o</FONT></TD><TD STYLE="text-align: left">Developing a best-in-class patient services center to assist LYMPHIR patients with administrative and
prescribing needs.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Marketing and Sales Initiatives:</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-size: 10pt">o</FONT></TD><TD STYLE="text-align: left">Launched a core marketing campaign to raise awareness among healthcare providers, ensuring that top CTCL
prescribers are informed of LYMPHIR&rsquo;s availability.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.5in"></TD><TD STYLE="text-align: left; width: 0.25in"><FONT STYLE="font-size: 10pt">o</FONT></TD><TD STYLE="text-align: left">Building an experienced specialized field sales team to partner with CTCL providers and office staff.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>About LYMPHIR&trade; (denileukin diftitox-cxdl)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">LYMPHIR is a targeted immune therapy for relapsed
or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It
is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin fragments. The agent specifically
binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis.
After uptake into the cell, the DT fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death. Denileukin
diftitox-cxdl demonstrated the ability to deplete immunosuppressive regulatory T lymphocytes (Tregs) and antitumor activity through a
direct cytocidal action on IL-2R-expressing tumors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">In 2021, denileukin diftitox received regulatory
approval in Japan for the treatment of CTCL and PTCL. Subsequently, in 2021, Citius acquired an exclusive license with rights to develop
and commercialize LYMPHIR in all markets except for Japan and certain parts of Asia. LYMPHIR was approved by the FDA in August 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>About Cutaneous T-cell Lymphoma</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">Cutaneous T-cell lymphoma is a type of cutaneous
non-Hodgkin lymphoma (NHL) that comes in a variety of forms and is the most common type of cutaneous lymphoma. In CTCL, T-cells, a type
of lymphocyte that plays a role in the immune system, become cancerous and develop into skin lesions, leading to a decrease in the quality
of life of patients with this disease due to severe pain and pruritus. Mycosis Fungoides (MF) and S&eacute;zary Syndrome (SS) comprise
the majority of CTCL cases. Depending on the type of CTCL, the disease may progress slowly and can take anywhere from several years to
upwards of ten to potentially reach tumor stage. However, once the disease reaches this stage, the cancer is highly malignant and can
spread to the lymph nodes and internal organs, resulting in a poor prognosis. Given the duration of the disease, patients typically cycle
through multiple agents to control disease progression. CTCL affects men twice as often as women and is typically first diagnosed in patients
between the ages of 50 and 60 years of age. Other than allogeneic stem cell transplantation, for which only a small fraction of patients
qualify, there is currently no curative therapy for advanced CTCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>INDICATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">LYMPHIR is an IL2-receptor-directed cytotoxin
indicated for the treatment of adult patients with r/r Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic
therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>IMPORTANT SAFETY INFORMATION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>BOXED WARNING: CAPILLARY LEAK SYNDROME</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>Capillary leak syndrome (CLS), including life-threatening
or fatal reactions, can occur in patients receiving LYMPHIR. Monitor patients for signs and symptoms of CLS during treatment. Withhold
LYMPHIR until CLS resolves, or permanently discontinue based on severity.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>WARNINGS AND PRECAUTIONS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>Capillary Leak Syndrome</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">LYMPHIR can cause capillary leak syndrome (CLS),
including life-threatening or fatal reactions. CLS was defined in the clinical trials as the occurrence of at least 2 of the following
symptoms at any time during LYMPHIR therapy: hypotension, edema, and serum albumin &lt;3 g/dL. These symptoms were not required to occur
simultaneously to be characterized as capillary leak syndrome.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">As defined, CLS occurred in 27% of patients in
the pooled population across 3 clinical trials, including 8% with Grade 3. There was one (0.8%) fatal occurrence of CLS. Of the patients
with CLS, 22% had recurrence. The majority of CLS events (81%) occurred within the first 2 cycles of treatment. The median time to onset
from Cycle 1, Day 1 was 6.5 days (range: 1 to 77), the median duration of CLS was 14 days (range: 2 to 40), and 75% of patients had resolution.
The most common symptoms included edema, hypoalbuminemia, and hypotension. Pleural effusion, pericardial effusion, and dehydration also
occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">Regularly assess patients for weight gain, new
onset or worsening of edema, dyspnea, and hypotension (including orthostatic changes). Monitor serum albumin levels prior to the initiation
of each cycle of therapy and more often as clinically indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">Withhold, reduce dose, or permanently discontinue
based on severity. If LYMPHIR is withheld, resume LYMPHIR following resolution of CLS and when serum albumin is greater than or equal
to 3 g/dL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>Visual Impairment </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">LYMPHIR can cause serious visual impairment, including
changes in visual acuity and color vision. In the pooled population across 3 clinical trials, visual impairment occurred in 9%, with Grade
1 in 8% and Grade 2 in 1%. The most commonly reported symptom was blurred vision. Of the patients with visual impairment, 67% had resolution
of their visual impairment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">Perform baseline ophthalmic examination and monitor
as clinically indicated. If patients experience symptoms of visual impairment, such as changes in visual acuity, changes in color vision,
or blurred vision, refer for ophthalmologic evaluation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">Withhold LYMPHIR until visual impairment resolves
or permanently discontinue based on severity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>Infusion-Related Reactions </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">LYMPHIR can cause serious infusion-related reactions.
Infusion-related reactions were reported in 69% of patients in the pooled population across 3 clinical trials of patients who received
LYMPHIR, with Grade 3 infusion-related reactions in 3.4% [see Adverse Reactions (6.1)]. Eighty-three percent of infusion-related reactions
occurred in Cycles 1 and 2. The most common symptoms included nausea, fatigue, chills, musculoskeletal pain, vomiting, fever, and arthralgia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">Premedicate patients for the first three cycles
prior to starting a LYMPHIR infusion [see Dosage and Administration (2.3)]. Monitor patients frequently during infusion. For Grade 2 or
higher infusion reactions, premedicate at least 30 minutes prior to each subsequent infusion with a systemic steroid for at least 3 cycles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">Interrupt or discontinue LYMPHIR based on severity
[see Dosage and Administration (2.4)]. Institute appropriate medical management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>Hepatotoxicity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">LYMPHIR can cause hepatotoxicity. In the pooled
safety population, elevated ALT occurred in 70% of patients, with Grade 3 ALT occurring in 22%; elevated AST occurred in 64% of patients,
with Grade 3 AST elevation occurring in 9%. For Grade 3 events, median time to onset was 8 days (range: 1 to 15 days); median time to
resolution was 15 days (range: 7 to 50 days); all cases of Grade 3 ALT or AST elevations resolved [see Adverse Reactions (6.1)]. Elevated
total bilirubin occurred in 5% of patients, with Grade 3 occurring in 0.9%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">Monitor liver enzymes and bilirubin at baseline
and during treatment as clinically indicated. Withhold, reduce dose, or permanently discontinue LYMPHIR based on severity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>Embryo-Fetal Toxicity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">Based on its mechanism of action, LYMPHIR can
cause fetal harm when administered to a pregnant woman. Verify the pregnancy status of females of reproductive potential prior to the
initiation of LYMPHIR. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective
contraception during treatment and for 7 days following the last dose of LYMPHIR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>ADVERSE REACTIONS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">The most common adverse reactions (&ge;20%), including
laboratory abnormalities, are increased transaminases, albumin decreased, nausea, edema, hemoglobin decreased, fatigue, musculoskeletal
pain, rash, chills, constipation, pyrexia, and capillary leak syndrome</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>USE IN SPECIFIC POPULATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>Pregnancy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><U>Risk Summary</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">Based on its mechanism of action, LYMPHIR can
cause fetal harm when administered to a pregnant woman. There are no available data on the use of LYMPHIR in pregnant women to evaluate
for a drug-associated risk. No animal reproductive and developmental toxicity studies have been conducted with denileukin diftitox.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">Denileukin diftitox-cxdl causes depletion of regulatory
T lymphocytes (Treg), immune activation, and capillary leak syndrome, compromising pregnancy maintenance. Advise pregnant women of the
potential risk to a fetus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">In the U.S. general population, the estimated
background risk of major birth defects and miscarriage in clinically recognized pregnancies are 2-4% and 15-20%, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>Lactation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><U>Risk Summary</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">No data are available regarding the presence of
denileukin diftitox-cxdl in human milk, the effects on the breastfed child, or on milk production. Because of the potential for serious
adverse reactions in breastfed children, advise women not to breastfeed during treatment with LYMPHIR and for 7 days after the last dose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>Females and Males of Reproductive Potential
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">Based on its mechanism of action, LYMPHIR can
cause fetal harm when administered to a pregnant woman.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><U>Pregnancy Testing </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">Verify the pregnancy status of females of reproductive
potential prior to initiating LYMPHIR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><U>Contraception</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><I>Females </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">Advise females of reproductive potential to use
effective contraception during treatment with LYMPHIR and for 7 days after the last dose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><U>Infertility</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><I>Males</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">Based on findings in rats, male fertility may
be compromised by treatment with. The reversibility of the effect on fertility is unknown.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><U>Pediatric Use</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">Safety and effectiveness of LYMPHIR in pediatric
patients have not been established.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><U>Geriatric Use</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">Of the 69 patients with Stage I-III r/r CTCL who
received LYMPHIR, 34 patients (49%) were 65 years of age and older and 10 patients (14%) were 75 years of age and older. Clinical studies
of LYMPHIR did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from
younger adult patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>You
may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Citius Pharmaceuticals
at 1-844-459-6744.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">Please
read Important Safety Information and full Prescribing Information, including Boxed WARNING, for LYMPHIR&trade;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><B></B></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>About Citius Oncology, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">Citius
Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In August 2024, its primary
asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic
therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing
therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending
patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology&rsquo;s competitive
positioning. For more information, please visit www.citiusonc.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>About Citius Pharmaceuticals, Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">Citius
Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class
critical care products. In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment
of cutaneous T-cell lymphoma. Citius Pharma&rsquo;s late-stage pipeline also includes Mino-Lok<SUP>&reg;</SUP>, an antibiotic lock solution
to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the
relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary
and secondary endpoints of its Phase 3 Trial. Citius is actively engaged with the FDA to outline next steps for both programs. Citius
Pharmaceuticals owns 92% of Citius Oncology. For more information, please visit www.citiuspharma.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left">This press
release may contain &quot;forward-looking statements&quot; within the meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting
Citius Pharma or Citius Oncology. You can identify these statements by the fact that they use words such as &quot;will,&quot; &quot;anticipate,&quot;
&quot;estimate,&quot; &quot;expect,&quot; &quot;plan,&quot; &quot;should,&quot; and &quot;may&quot; and other words and terms of similar
meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and
uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause
actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Pharma and Citius
Oncology, are: our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; our need
for substantial additional funds; the estimated markets for our product candidates and the acceptance thereof by any market; the ability
of our product candidates to impact the quality of life of our target patient populations; risks relating to the results of research
and development activities, including those from our existing and any new pipeline assets; our dependence on third-party suppliers; our
ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements
and relationships; uncertainties relating to preclinical and clinical testing; the early stage of products under development; market
and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire,
close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well
as other risks described in our SEC filings. These risks have been and may be further impacted by any future public health risks. Accordingly,
these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance
on these forward-looking statements. Risks regarding our business are described in detail in our Securities and Exchange Commission (&ldquo;SEC&rdquo;)
filings which are available on the SEC&rsquo;s website at www.sec.gov, including in Citius Oncology&rsquo;s and Citius Pharma&rsquo;s
Annual Reports on Forms 10-K for the year ended September 30, 2024, filed with the SEC on December 27, 2024, as updated by our subsequent
filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in
our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><B>Investor
Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify">Ilanit
Allen</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify">ir@citiuspharma.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify">908-967-6677
x113</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify"><B>Media
Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify">STiR-communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify">Greg
Salsburg</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify">Greg@STiR-communications.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">7</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  U 2H# 2(  A$! Q$!_\0
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M3333::::;3391112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX&U'QM)X:35(_#LOBV\\,:1I<_B*;0X]:U>+29M7>\ET^+4[Z*U>*.YE5O\
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MX)\/Q_ OX)W<>A>$= TKPWH\=U=:+J37-RFF:-:65DEQ<,JM/,L DF8 R,Q
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M R^+'T@WL>GWMSI(T8ZX=#DN+>"<W@TV:2,0/^37_!"'_@X$^*W_  5Q^/\
M\8O@E\1_V=_A[\(X/AM\'O\ A:>F^(_!/C#Q)K<NH2Q>-?#'A*71+[2]=L B
MQR)XD%]'?P7\;0M9&W:TF%SYUO[#\-O^5574?^T)OQ6_]9#\8U_,G_P97_\
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M/E&X1H$/B;4]4\9::9([420RR_\ ")!9KATN4B@CC:TD_'/_ (*JZA%\%_\
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MK>V74VT"/4IDFU"YOKRZ_H1_X)+R>(Y?^">'[,[>*1<C4AX8\4QVOVK>)?\
MA'(?B+XQA\(%?,);[,?"::*;/!V&T,!C CV '$6594LFRO/LLP]3 QQ]3V53
M!5*DIQ5X5I*=/GE)KDE0FFX2=.I3G3FHPE=/3A#/,\?$.=\+9WBZ.:3RNE[:
MEF5*E"E-J-3#Q=.K[.,(RYX8JG)1J0C6I5:=6G*52/*U^4A_X+^^+=)^,DGA
M#Q+\$_ \7PWTWXE2^&M;\3Z1XD\07>MP^#+3Q,^EWWB'3K9K<V5[J,.C1R:G
M;VFU+>\G1;=7A242)_33:W5K?6MM?6-S!>65Y;PW5I=VLT=Q:W5K<1K-;W-M
M/$SQ3P3Q.DL,T3M')&RNC,K G_-<O=+U3QEJ_P 0/$?A_3KN]TO1/[0\9:S*
ML8WZ7X>U#Q7I>AP:A=QJS;(QJWB;1+&789!'+>HS'RE>1?[,O^"6_P"V%H'C
M?_@GY%XN^(>M".__ &6O#^O>$?B->221R7J^$OA]H)USPQK7D2/')*)O 2V&
MEI<3S,VJ:WH6KL)_-,B1>EQCPS@\#@\%B\JPRI.%6GA,92IRJ3E*IB84_JU2
M495*CC.592I6CRJ7MH66S/'\/>,\?F689E@,[QKK*I0K8_+Z]:-*E&%+!U*R
MQE*,X4J,94X8=PKWESRC["K>6DD>>_\ !1#_ (*X:C^QW\:].^"GP[^'7A?X
MB:QI_A/3O$/CJ_U_7-2L(]"U+Q!)+<:)X>@MM,B,@O5T&*UUZ]EN7:.2SU_2
M!;JK)<[OTK_9%^.MW^TO^SA\*OCEJ&A6_AK4/B!H5UJ-_H=G/+=6>GWVG:WJ
MFA7D5G<3DSRVCW.ERS6SS8F,$J"55D#*/X,_C?X[\=?'WXA_%/\ :.\3V5X8
M/'?Q(NY;N^E+/9:=?:Y'J6HZ%X4LKAPHGBT#PUI4.G6\4>]K/3;'3Q<;/M-L
M9O[,/^"0.H2ZE_P3L_9WEGFCEFMX/B9I[;!&IBBT[XQ_$*RLX9%C "R)80VN
M2P$DBE9G+&3<V7$_#N!R?A[+:M*C#^T(XFAA\=B8SG*52K4PM:K5@TYRIJ,*
MJ48VA!J-.#UYW??@KB[,^(>*\XI5L14>52PF)Q66825.G"-*A3QU"A0J1DJ<
M:KE4H7G-RJ33E5FM/9JWU1^U9\>=-_9D_9Z^*?QQU&UM]1;P'X:EO-'TF[G>
MVM]:\3ZE=6VB>%-&GFB5IXK?4_$>I:99W<T"/-!:2SSHI,5?B_\ LG?\%N_%
MWQU_:'^%OP=^('P?\$^#O#OQ(\1+X27Q)HGB/6KC4-.US5K2Y@\,1QVFI0_9
M;M-4\1G2]&EB,L,JIJ)G@:66%+6XN?\ !P!\;O["^%OP=^ .F7:K>^/O$^H_
M$'Q1!$5\V/P[X)MUTS0K6[5N1::SK^O7-[;F)2YN?"+B22) ([G\&_CG^S[X
MR_90MOV4?B(EU?6NK_%;X0>%/CEIM_)$UN=$\4OXIU35;'2;="%DCN=#\.GP
M-?W:2-YT=_J4N]8OEC3JX8X;RO&Y-">8TH/'9O/'PRRI.52,J4,-AI*-2$85
M(1?+44J[YHSYE#E2:=CDXRXOSO+^(IT\IKU(Y9D-/*YYS2IPHRA6GC<7%RI5
M)3I5)KFI..&7).GR2GS-IJZ_O[HKR_X)_$[3/C3\'_AC\6M'1(M/^(W@7PQX
MQBM4E$W]GRZ]I%I?W>ERR G-QI5Y-<:;=*3N2YM94;#*17J%?F=2G.E4J4JD
M7&I2G.G4B]XSISG3G%^<9PDOEIHU?]CI5:=>E2K4I*=*M3IUJ4UM.G5IPJTY
M+RE"I"2ZZV>J:11114&A_B^?LES:Y\%O^"C-M^SEX_\ &%QX-\+^./VF$_9N
M^,NN>,@NK1^&YKGXH77P];XA>)C<7>BYU?X>:Y>W/B+4=92XL;K^SX_$=C)'
M-INLZII5]_HU?\$0_@_\9/V?_B?^VC\&/BCH=_HS^ ]2^&%E=12QM)HLVNW:
M^,YH-6\.W\D<:WECXD\-1Z/JZ7-H!]KTEM!GOXX76RC7^;+_ (.;/^"$OQM\
M+?M ?$?_ (*)?LG?#S7?BC\'OC+J4OC/X^^ _ 6B:AKWC#X2?$J:V1_%WQ!?
MPYI<%YJNK_#OQW<P7'C#Q#XAL8;L^$O%-[XDF\0Q:7X=N=(O!\]_L;?\'?'[
M<W[.OPR\,_"[XY?"+X7_ +5]OX/TBRT'2/B+XDU[Q)\/OB[J^EZ9:M9Z9'XX
M\6:7#XFT+Q?J%A;)9VPUZ?P=8^(=4BMYKKQ'JVN:U?7.L-[F'SC$T<IQ^46C
M6PN-]E.,9R=\+7IUJ=656EH]*L:;A.'NKF<:J:ESJ?S>*X>P>(SW+,_3EA\=
MERKTZDJ<5;'8:KAZU&%&OK%WH3J^TIU/>DH<U%KD<'3_ -.JO\FW]NC_ )6>
MO$__ &DV^ G_ *LGX7U_5_\ \$(?^#A[XU_\%6OVQ/B]^SQ\9?@Y\*/A5H>C
M_ F7XK?#(?#H>,K_ %;^T?"7C/PSX;\8:9XIUSQ!KNHV>IKJUGXZTK4=&-EH
M/AV+3$\/7]O/-J-QJ4&W^4#]NC_E9Z\3_P#:3;X"?^K)^%]>-%--I_RL^@FT
MTFN[_(_UDJ_RJ_\ @[=_Y3#^,_\ L@?P,_\ 3'JE?ZJE?Y5?_!V[_P IA_&?
M_9 _@9_Z8]4HA\7R8Y[+U_1G^HM\*?\ DEWPV_[$'P=_ZCNG5_GP_P#![#_R
M=%^Q+_V0/X@_^K#@K_0>^%/_ "2[X;?]B#X._P#4=TZO\^'_ (/8?^3HOV)?
M^R!_$'_U8<%*'Q+Y_D$OA7R/Z1?@MHE]XE_X-=+7PYI@C;4O$'_!&3XB:)IZ
MRLZQ&^U7]E#Q586@E:-)76,SW$8=DCD<+DJCD!3_ "O_ /!ESX@LK/\ X*+?
MM(>&9@RWNN?L8>)]5LI6>)8F3P]\;?@C!=6H5Y%EDNI4U^*YA2*-P+>RO9)"
M@C7=_;-_P2$\.:-XP_X([?L&>$O$5E'J7A_Q3^Q5\)_#FNZ=*6$5_HVM_#NS
MTS4[*0J0PCNK*ZG@<J0P60D$'!K_ #D?BK\%_P#@H)_P;5_\%'(OB[X,\*7S
M^&_#'B7Q5I/P>^*_BCPOJ&M_!+]H?X.^(6FC?PIXCU#2[BRMHM9O_#XLAXQ\
M'VVO:-XS\'>([*VUK2;B"&'P[XAO6M>9=7M][$].1]$E<_T._P#@OYJFGZ/_
M ,$;_P!OV[U.ZCL[:;X)G2XY90Q5]0USQAX6T32;4;%8^9?:KJ%E91$@*);A
M"[(FYU_EO_X,B[*[D^(O_!1+44MIFL+7P7^S597-VL;&W@N[_7/C5/96TLH&
MU)KJ'3=0E@C)#2)9W#*"(FQ^3W_!1W_@X=_;E_X*\_"31?V,-&^!?@OX?^#?
M'7BGPQJ'B'P)\$].\?>//B-\7O$'AO4_[;\->&%%U>W\UQX>M==M-*\1P>&=
M&\,SZM<^(-!TJ^DUJ:VM!8'^S/\ X-F?^"7/Q+_X)O\ [%_BS7_C]HO_  BW
M[07[4OBO0?B)XR\$RLIU3X>>!?#6B3Z=\-/ WB=4:2*+Q?9C6_%GB;Q#91R;
M]$N/%D7AJ^CCU70]0#%N6+3W;6@7YIIK9+_,^W?^"E?_  19_88_X*FV.FZE
M^T-X)UOP]\6O#FD?V%X3^//PLU:V\+?%'1=%2:YN[?0-0NK[3=;\-^+_  Y;
MWUW<7=KI'C'P[KBZ3)=:B_AVYT.?5-0N+G_/0_X+)?\ !![XZ_\ !%R7X9?M
M"^!OCPOQ4^"7BOXD6O@[P3\4]"L;WX6_%7X<?%%-&UGQGX;T;6M&T_Q!J[)=
M7>B^%O$6H>'?&WA'Q RS7/AC4GU32?"-S/HEMJ?ZN?'C_@[-_P""A/[+/[7O
M[3GPD\7?LV?"#Q-\,O"?QO\ B?I/PL\-_$_P9\1/A?\ %C1?AMI_B[6=.^'Z
MZMJEAX@M-/U*&[\-VNF:D][>>")+S4)+B:6'6);>2%T_(#_@H1_P5Y_X*(?\
M%[-<^%O[-NB? JQ;PMX8\81^,O!?P!_9S\'>-?&FN>(?';Z;J/ABQ\9>+]2O
M+K7]6U.ZT'1O$FNZ3IUU:67AGPYHNFZ[JMQJ%K)-,^H(XJ2_P]==!2<7?1W/
M[G/^#9G_ (*!_%K]O_\ X)QPZS\??$NH>-OC)^S]\5?$/P'\2^/M:>6Y\1?$
M+P_I7AGPCXR\$^+_ !/J)A2+4_$?]A^,1X2U?5)IKC6M=N_"#^)O$4USK&NW
M.H7_ ,@?\',7_(]?LB_]BK\7_P#T\?#ZOTH_X(#?\$U_%G_!,+_@G]X<^$'Q
M4_L@?'3XG^-M=^.'QHM-&N8=3L_#7BKQ3H_AWP_I/@2'7()9K?5_^$.\(>%/
M#^GZI<:;*^@MXKE\37&A3:A872:QJ?YK_P#!S%_R/7[(O_8J_%__ -/'P^KZ
M/A"W^L.#MMR8NW_A-4/A_$J_^I>:7W]IE_\ ZGTC\XOA'\>_^"L_BO\ 9N\*
M_LY? ;0/C_?? 8Z%K6B:)_PJGX&7DSZKX;UGQ%>3ZI'_ ,+1T#P/-X@CTI-9
MU'4=/OK^Q\4V%L(+FYTS5[J:V4Q)^OO_  1V_P""17Q6^"WQ0TS]JG]J'1(?
M!>O^%;+48_A3\+9KRPU/7K?5=<TRZTFZ\9^+WTR\O-.TC[#H]_>6NA>'7FN=
M7&H7TFI:M%H=SHUE;:A^I_\ P1[_ .4;7[+/_8J>*_\ U9?C:OTKKMSGB2O&
M69Y9@\'@\#3J8G$T<57H1E]8Q*C5J4ZDIR<8Q4ZT4U4E[\N6<XQ<5)M^7PQP
M-A90R+/<SS3,\WK4<#@<5@,)C*D?J> <L/1K4:=&"E4G*GAI2BZ4'[*'/3IS
MJ1J.$8Q_AE_X+W?\I"_$7_9*_AE_Z:[ZOL'X3_\ !NY_PLWX7?#;XE_\-@?V
M)_PL/P!X.\<?V+_PS]_:7]C_ /"6^'=-U_\ LO\ M+_A=MA_:']G_;_LGVW[
M!9?:_*\_[);>9Y*?'W_!>[_E(7XB_P"R5_#+_P!-=]7]CO[*/_)KG[-G_9 O
M@[_ZKOPY7L9GFV/RKAOAJ> K^PE7P_)5?LJ53FC##J<5:K":5I-N\;-WLW8^
M<R/A[)^(>-N.:>;X3ZW#"XUU:"]OB*'LYU<8Z<Y7P]6DY<T(Q5IN25KI)ML_
MSXOVN?V?/^&5?VC?BC^S]_PEW_">?\*VU;2M,_X2W^P/^$7_ +:_M/PUHGB'
MS_[!_MKQ%_9WD?VO]C\K^VK_ ,S[/]H\R/SO(B_O_P#VS?C@G[-_[+'QS^-"
MW-O::GX*^'^LS>&)+HJ()/&VL(GA[P-;2 _?2Z\7ZMHMN\:Y=TD95&37\2/_
M  5U_P"4C?[47_8U^%O_ %6W@NOW4_X.(_CL/#OP<^#?[/.EW074/B5XOO\
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MK5U&52K.;F_9N.-A%2?-4EC54=2I1YX_@Q_P1;^%?AKXX?'C]HOX2^+H(Y=
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C<I2:2Z)-)=$A1A"":A"$$VY-0A&";>[:C&*;?5M-OJV?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>ctxr-20250107.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 8qI5s7xRiXgen8uOYHxcWa2OScP9zp5yGZlBvGd7Hbl6Py8gsaqdWC0zZ2lGoUQD -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:CTXR="http://citiuspharma.com/20250107" elementFormDefault="qualified" targetNamespace="http://citiuspharma.com/20250107">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://citiuspharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="ctxr-20250107_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="ctxr-20250107_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>ctxr-20250107_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>ctxr-20250107_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24c -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://citiuspharma.com/role/Cover" xlink:href="ctxr-20250107.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://citiuspharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46118222242128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jan. 07, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan.  07,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Citius
Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001506251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-3425913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11
    Commerce Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">1st Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cranford<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">967-6677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par
    value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CTXR<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M"RBN^"KXUAP<$_<H2Z4>W> N'GF!(^()CZR38/#QQ*<\29P2</R[%_7*>[K
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M;%!+ 0(4 Q0    ( &A))UIT:W_<[P   "L"   1              "  :\
M  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( &A))UJ97)PC$ 8  )PG
M   3              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#
M%     @ :$DG6I:I);]B!   (A$  !@              ("!#@@  'AL+W=O
M<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( &A))UJ?H!OPL0(  .(,
M   -              "  :8,  !X;"]S='EL97,N>&UL4$L! A0#%     @
M:$DG6I>*NQS     $P(   L              ( !@@\  %]R96QS+RYR96QS
M4$L! A0#%     @ :$DG6JK$(A8S 0  (@(   \              ( !:Q
M 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( &A))UHD'INBK0   /@!   :
M              "  <L1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+
M 0(4 Q0    ( &A))UIED'F2&0$  ,\#   3              "  ; 2  !;
H0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /H3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea0226990-8k_citius.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://citiuspharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>ctxr-20250107.xsd</File>
    <File>ctxr-20250107_lab.xml</File>
    <File>ctxr-20250107_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ea0226990-8k_citius.htm">ea0226990-8k_citius.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0226990-8k_citius.htm": {
   "nsprefix": "CTXR",
   "nsuri": "http://citiuspharma.com/20250107",
   "dts": {
    "schema": {
     "local": [
      "ctxr-20250107.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ctxr-20250107_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ctxr-20250107_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ea0226990-8k_citius.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://citiuspharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-01-07",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0226990-8k_citius.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-01-07",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0226990-8k_citius.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://citiuspharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001213900-25-001408-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-25-001408-xbrl.zip
M4$L#!!0    ( &A))UH>_SW)+P,  .\+   1    8W1X<BTR,#(U,#$P-RYX
M<V2U5MMRVC 0?>],_T'UNVTN(0D$DFG))&&&-"GDUKQTA"Q $UER)!E,OKZ2
M;UP,%&CK)WEUSME=[:[LYD7D4S#!0A+.6E;9*5D ,\0]PD8MZ[%O?^VW.QT+
M7)Q__@3TT_QBV^"*8.HUP"5'=H<-^1GX#GW< ->880$5%V?@"=+06/@5H5B
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M]$)XEC!Z/CH^^CA"A$8L3NCZ?/1U,;Y8S.;S$<IR3&.<,DK.1Y2-?OSACW]
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M.+TGSXQWX=.6N:;&9E*'I:D)BA&+,1"-4HM*L2<B_K$59^R$I_M>* RE:RX
MJSH:FBPH.NS>0$!JN5]&EAS3+)$#6"\DIM3YZ09@UCCUT'1!<0*8@T]):KU?
M4A:/)$WE_0!,^P<4F]@U+;!AG1=3&10QH#V0F2("52'A8'/Y(E?G8IDTL+$-
MO4]X#-M=_-3B8!'2'0ZDJ A#,LX328W;$#T,&4K7] !6=6XT65#$V+V!K)1R
M5.C]0W))XT&(U#H_@&@V[7A4H@#A:#OK0T.H?8)QE6013DLO5V);UM$\B]8U
M(*!='1)#&!0HD#L0EC) ,5.$> 7F7P3S8;@TE'Y@,:S:4:EE 8*B>^O#1.J]
M0#+;<MYR#<\XL-393=D>L_7]64 7!"@]YHR[MJ6\!8JG&>B2YDF^E\_3W6PW
M*\(MC3,EKMB S"DF]/(@6 !,Z0R4,B1UJ!1ZZ7EUEX#F\B%&L#FZS"T!=I-M
M"MJ:@$BP&@-H.&B+9TJ]$#$3(Q/'Z9S&9/<SV8/M,G1NF0!LMJ'01 %187<&
M8%&)4:%&0NX%C#N>;##?+Y*H9ZHPA6[1@(RVV=!5 <$!6 /HJ-1H,9_YG$F6
M>#>/!:C)0U(^#]Y#":AW"TN/[38S@#@@=+H= @2)(-2.\@G2G$:,/[/&XPXS
MMA4#X'[&8GB%TA/E%JI!36BCU1D2$&!#? *8M4(_E,^D(";?XRDJ0+(&+\1=
MQ+$X4%GUSW5"R3'8?JO6+5T==MM,680!D02[ _BIE!_4!R1CT"T-!9KI&YHZ
M]0_-="@TTZ"AF;X'FN4K"P2:DS<T]<0_-"=#H3D)&IJ3=T$C.M[K6#,3'V_Y
MDKW:'LX&E5Z0,:U:@3G(PL/%\-8'BPR0ZQD9XA.38F%UR^\X>TEH!"^9(;D7
M8 #35FHT;7CHV WV\5,OB%6<U[&F7)3W?DF4S,\HTS9I'V)*37B0M(WU#BZE
MVB<2=RS+<?KOY+GS1-PN]H*'U; 5DI8R/%1L]OJ *6.0"/)Q8EWA*F]H6%\E
MT\K=O0)LL75X!;A1& 0$-D?F*\#EU9-2Y+J;):.<8&!$:!<[ZV2+J;J/&V5A
M=+%IR.CAXGLM-#Z^R#*[2WKWR"C\@( I<=73D#G5VWIY$#T.F-)[O9"A0N?I
M:KS,,)'9A^]&F;.97;=33^2J((C>U=T8T[0J=]R;O_(D%WN>L<UF2ZN[/+;G
M!@&=JU[NM*EZW"H*HO>[G.DD5%K4%CO&8L'2)$KRA*Y_$2>?/,&V5ME$KH"
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M7H::%:"5?$:LJ@+])BM!12VVWR]O;KH6G\1FM4G\M<(9$5O^"U!+ P04
M" !H22=:OL?ZFUP'  #=5P  %0   &-T>'(M,C R-3 Q,#=?<')E+GAM;,V<
MWU/;.!#'WV_F_@=?[CF$!'H]*%P'4M+)E!:.T/;N7CJ*K20:9"DCR23Y[T^R
MXS0_+'EY\<(#!&<E[?>SLNRU)%^\7Z8\>J9*,RDN6]VCXU9$12P3)J:7K:^C
M]M6H/QRV(FV(2 B7@EZVA&R]_^O77R+[<_%;NQT-&.7)>?1!QNVAF,AWT1>2
MTO/H(Q54$2/5N^@;X9D[(@>,4Q7U93KGU%#[1='P>?3FJ'<:1^TVH-YO5"12
M?7T8;NJ=&3/7YYW.8K$X$O*9+*1ZTD>Q3&$5C@PQF=[4=KP\7O\4Q2\X$T_G
M[M>8:!I97D*?+S6[;+EVU\TN3HZDFG9ZQ\?=SC^?;T?QC*:DS83C%M-66<K5
M4E6N>W9VULF_+4T/+)=CQ<LV3CJE.YN:[;<L8+_EB6;G.G?O5L;$Y&&O;2;R
M6KC_VJ59VQUJ=WOMD^[14B>M$GY.4$E.'^@D<G]M]#:MQLRP3,]G1*7$!:WC
M##I]:3NE]38O.E-T<MF*S5+9%GIOCKO';UW]O^\8F=7<=D[-7-]J19V=MN>*
M:BI,+O?6'M@I0I?&=BF:E!6Y]E_BG6'&%5AWFF[4=CTL2VU[]F-AN7:F=(?+
M>,<#[B(A]^26O3KGK6E\-)7/G80RR[UWZCXX%J<Y!_O/C[RAJ[$VBL2FK(F3
M,>5Y_3^LS9Y)IP&O2A*/ML9JIW8M]GW:#MR5BB.I$JHLZ[(NHN*=<!UVT+5%
M9TZ4K:@=SQC?1'JB9.JCLR8A/8YN@[)--$/SRK:?.!\&G$RK<>Z9 'EV,8!6
MJL$B^H'J6+&YXU(#=L<2R+>'RK="6\.8RW/G@4Z9\]>YXBZ[U!T,CPN>(D#P
M)Y@C15 M4@2NA,@(?Z!SJ6K [UH">9]B\J[2AH3Y[XPH0Q5?04@?& -AO\&$
M[5&(Q/M1$:&9XP,!?F@-)/X'ZHV'1R,2\M&,<NY2.2) O;S*'HC]+29VO\Y7
M /[FV5W?[:4%SGZK"!#_GZ\%_X%:I C<4\5D8B_I"L#^P!A(_0R3ND<A*N\;
MD4!I;TS!^0\^[#UY2*@'3,>$%QX-[#$=QEUA#D6.DG/6RD3%_B\E"@Q]RQB*
M'"4-K9'8,/!^IM2.,\%1Q6\-18Z2@-:);)CYC3#,K-RS_R]9.O[YX'27]:$5
ME#%*TND3A<*V?-(@C)O2"/'=MX0R1LDU0^)0./>M'D7X4"1T^8FN0J /3*&D
M47+,H#P4U/>*I42M1BRN'S0.;:&P43++L$ 4VH]D.4RL*C9AQ:1@/71O$2A[
ME+02)!<E!$,12S676X^+^S*SY^.J+Y/@D%Y3$!H.E'SS!=)1@G*5)!:77O^Y
M98)V0Z&H- ?/$>$%("#SE6#OO0Q[#XX=)0^ME?E*L)^\#/L)'#M*+EHK$Q-[
MWWZ\4X]RX9F!]AI#D:/DHC42,8'G5YH[=:_D,RO61M51/R@!18^8HH;%HG;X
MXB(/Z>VE)90W8KI:+0Z3\[W4AO#_V+SN3K+:'LH<,7$-"6WZ 6,1=_?0PK>4
M:,\$RA<E5ZV4TS12%V%%B;_[[EI @:(DH%5B&N9Y*]W<QTR*X//80RLH5Y1,
MTB>JZ8'7+2;6WE-_ZVOP"C:4875?1L,8ORMFK =]F::96#^C\<R*>4RA>%'2
MOZ"\AE&/)&=NE;N8?K9WB(H17LVYR@X*&279\PMKF/"]HB[2U-YVY^NXW&X#
M=3>9^$;>D#V4.$JN5R\4E_Q0ZXRJE_*O* 6- DK:!Q7=]#A#X\P.>ZMN;_SH
M=LQX1ID#*RAKE)3/)ZIAME_DHR)NS]YHE8XE]V\/J32$$D9)\ +2&H:\XT<U
MWCT3*%B4S*Y2#M*8<+.,9T1,J7_U0K4E%#!*IA<2AS;V3D%C[_2%8R]*QN<3
MA<2V6!MNSZB[,6=3XM])%BP WF>#23P@M>G]>_F6'[>;6Z6Y'P/[H1J[QQ0*
M'&>+9$A>TZBSA!F:%"X-F" BMBG59E^;)SNO+P4- ,X>2J!HE,?[WRGGGX1<
MB!$E6@J:%+?ZH2?\WB+0*"#.(=;(10G!-\DS2TGE"T&5YQSPF$*1(\X=>N3A
MK+TL%C5OKCW%:SM"Q'TEH. 1)Q'#8I'6IQGJ?&;/] ,Q9.UAB+^O!)0_XH1B
M6"S:^GG5MQ>>J0S/F>\90FDC+H6ME(8">902SJ\SS035P;%ESQ *&7'-:Z4T
M%,@W*553.ZA]5')A9NN]G2'8G@)0Z(@K6X-2<> O?^XC+_:_!<E76(/?3H"(
MW2L2Z[4;<>P64A17<I$0Y:$>LH=R1]U8Z1?:,/D[,Z-J^_XI=V9H\[;0HH?Z
M4M HH*2K4-$XU]:MG?S!2^N.'90W8F):)0QGSU0VYBP><$F"]^4[9E"^B%EH
MA2P4O-=$/*EL;N+5O9(QI6[Z1&_.-D!"!*P &A+$_/1%*' >%\@T=9N)9/PT
MFEG1^BXS^5M,K7_!AP;!<M#08&[B! A'N@O2/S=ZT>1Z]4 G5+EE"H]T::YM
M0T_AFR) <6A\4-\H!,90$::+SH&N6WO O:>V^,;]<N]BM4?^!U!+ P04
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M442LJ["/F-@EL*[UX)$"VD+L.,01%D"?]0HM5R>)2]SC#G'6-'O0$M2T.,0
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M862Z EN9(G]75S?\[KO[V_631KESU:K]L<FJMTR5SWY)C5?(?G UV\\=/N]
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M8ETBC(*>)R/3(QN"OV#/V'!I4C476^^.KXZ'VWRM9' 9,X=.MTJ@>-D8M:'
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MX]WH_.S5_P-02P$"% ,4    " !H22=:'O\]R2\#  #O"P  $0
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M+FAT;5!+ 0(4 Q0    ( &A))UJ 6(<_32(  ,#.   <              "
M 9 H  !E83 R,C8Y.3 P,65X.3DM,5]C:71I=7,N:'1M4$L%!@     %  4
*5 $  !=+      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>ea0226990-8k_citius_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ctxr-20250107.xsd" xlink:type="simple"/>
    <context id="AsOf2025-01-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001506251</identifier>
        </entity>
        <period>
            <startDate>2025-01-07</startDate>
            <endDate>2025-01-07</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-01-07" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-01-07" id="Fact000004">0001506251</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-01-07" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-01-07" id="Fact000010">2025-01-07</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-01-07" id="Fact000011">Citius Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-01-07" id="Fact000012">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-01-07" id="Fact000013">001-38174</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-01-07" id="Fact000014">27-3425913</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-01-07" id="Fact000015">11     Commerce Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-01-07" id="Fact000016">1st Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-01-07" id="Fact000017">Cranford</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-01-07" id="Fact000018">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-01-07" id="Fact000019">07016</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-01-07" id="Fact000020">908</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-01-07" id="Fact000021">967-6677</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-01-07" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-01-07" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-01-07" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-01-07" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-01-07" id="Fact000026">Common stock, $0.001 par     value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-01-07" id="Fact000027">CTXR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-01-07" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-01-07" id="Fact000029">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
